COLLPLANT BIOTECHNOLOGIES REPORTS 2025

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL

RESULTS AND PROVIDES CORPORATE UPDATE

REHOVOT, Israel, March 26, 2026 -- CollPlant

Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on

its non-animal-derived rhCollagen for tissue regeneration and medical aesthetics, today announced its 2025 financial results and provided

"Over the past year, we have made meaningful

progress across all fronts-from advancing our collaborative programs to building momentum in our proprietary pipeline and commercial product

portfolio. In aesthetic medicine, we achieved a development milestone that triggered a $2 million payment from our collaboration partner,

AbbVie. We also expanded our commercial reach by broadening our distribution footprint into North America through a new partnership with

a U.S.-based logistics center, while strengthening the European distribution network for our commercial product, Vergenix STR.

We further strengthened our pipeline by leveraging

new preclinical data to refine the commercial design of our regenerative breast implants. In addition, we expanded our intellectual property

portfolio with newly granted patents in the United States and South Korea covering our photocurable dermal filler technology.

CollPlant also continued to drive innovation beyond

its core development programs. Using our rhCollagen, researchers at Mayo Clinic created the first fully humanized 3D bioprinted skin model

designed to serve as an alternative to animal testing in preclinical research. In parallel, we reported results from a comparative study

demonstrating that CollPlant's rhCollagen-based bioink, Collink.3D , outperformed Matrigel , a leading extracellular matrix,

in supporting structured tissue formation. We believe these findings reinforce the potential of Collink.3D as a consistent, tunable,

and animal-free alternative for advanced tissue engineering and research applications-an opportunity representing an approximately $100

million market that is projected to grow at more than 10% annually.

Mr. Tal added, "These achievements collectively

highlight how our rhCollagen platform enables animal-free solutions across healthcare and industry. Its applications range from drug discovery

and regenerative medicine to advanced tissue modeling and safety testing for cosmetics and pharmaceutical products."

2025 and Recent Corporate Updates

rhCollagen 3D Bioprinting Portfolio

In February 2026, CollPlant announced the launch

of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications. BioFlex

is engineered to support the biofabrication of advanced tissue models for drug discovery, as well as the development of engineered tissues

and potentially transplantable organs. The ready-to-use system includes Collink.3D 50, a biodegradable polymer component,

together with proprietary photoactive agents optimized for high-resolution DLP printing.

Designed for both academic laboratories and industrial

R&D environments, BioFlex enables advanced applications in 3D bioprinting, tissue engineering, and regenerative medicine, helping

accelerate the translation of research concepts into functional tissue constructs.

In October 2025, CollPlant announced that a scientific

article published in Archives of Dermatological Research reported that researchers at the Mayo Clinic developed the first fully

humanized 3D bioprinted skin model using CollPlant's plant-derived rhCollagen. By combining rhCollagen with key human skin cell

types, the model provides an innovative, sustainable, and ethical alternative to animal testing in preclinical research, with potential

applications in cosmetic and pharmaceutical testing, disease modeling, and drug development.

Also in October 2025, CollPlant announced the

expansion of its distribution footprint into North America through a new partnership with a U.S.-based logistics center. The logistics

hub provides full cGMP-compliant storage and distribution services and will serve as a clinical supply depot. This expansion is expected

to support CollPlant's growing customer base for its rhCollagen and BioInk product lines across the United States and Canada.

AbbVie Collaboration

Under CollPlant's existing development and commercialization

agreement with development partner, AbbVie, CollPlant has granted AbbVie a worldwide exclusive license to use CollPlant's rhCollagen technology

in combination with AbbVie's proprietary technologies for the development and commercialization of dermal and soft tissue fillers. AbbVie

is conducting a review of interim results from the first cohort of patients enrolled under the clinical trials initiated in 2023.

Next steps for the program are to be determined by AbbVie upon concluding their assessment.

In February 2025, following a development achievement,

CollPlant received a $2 million payment from AbbVie, according to the development and commercialization agreement.

Regenerative Breast Implants

In August 2024, CollPlant initiated a preclinical

study evaluating its 200cc clinical-sized regenerative breast implants, which were manufactured with enhanced durability. The surgical

protocol was refined to enable implantation through a small incision while minimizing the risk of implant displacement or inversion. Analysis

of MRI and ultrasound imaging conducted in 2025 confirmed tissue integration and vascularization, providing valuable diagnostic insights

for future clinical applications. At six months post-implantation, one study arm demonstrated promising outcomes, with the implant showing

vascularization and rapid tissue ingrowth throughout the clinical-sized implant. No complications, including capsule formation, calcifications,

or local tissue reactions, were observed. In addition, implant volume retention and mechanical properties were maintained in the successful

Following completion of this study phase, CollPlant

plans to further optimize the regenerative breast implants to support long-term durability and remodeling of the newly vascularized tissue.

Mr. Tal added, "CollPlant's breast

implants currently under development represent a paradigm-shifting approach, designed not only to regenerate breast tissue but also to

offer inherent safety advantages. Following upgrades to our bioprinting process and related manufacturing capabilities, we have been able

to produce and test commercial-sized implants. We are encouraged by the results observed to date. This program represents one of our lead

development initiatives and has the potential to position CollPlant at the forefront of regenerative medicine."

In the United States alone, hundreds of thousands

of patients each year experience complications associated with breast implants, ranging from autoimmune-related symptoms to the rare

but serious condition of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). CollPlant's breast implants, composed

of the Company's proprietary plant-derived rhCollagen and additional biomaterials, are designed to support the regeneration of

breast tissue without eliciting an immune response. As such, they may offer a transformative alternative for both aesthetic and reconstructive

procedures, including post-mastectomy breast reconstruction for cancer patients.

Intellectual Property

Photocurable Dermal Filler Product Candidate

In February 2025, CollPlant announced that it

had been granted U.S. Patent No. 12,186,449 related to its photocurable dermal filler product candidate. The patent covers polymerizable

solutions comprised of modified rhCollagen and additional components such as hyaluronic acid and is expected to remain in force until

More recently, CollPlant announced that the Korean

Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently

under development for the aesthetic medicine market. South Korea represents one of the largest target markets for CollPlant's photocurable

dermal filler product candidate.

rhCollagen Curable BioInk Product Portfolio

In November 2025, CollPlant announced that the

Japan Patent Office (JPO) granted a second patent under Patent Application No. 2023-101072, securing intellectual property protection

in Japan for CollPlant's portfolio of rhCollagen-based curable BioInks through 2038.

The newly granted patent relates to CollPlant's

innovative curable Collink.3D BioInk product pipeline, which represents the first and only line of human collagen BioInk products

based on chemically modified plant-derived rhCollagen that can be mass produced with high purity and consistency. Collink.3D enables scalable

and reproducible biofabrication of tissue models, tissues, and potentially organ transplants, while closely mimicking the native properties

of biological tissues. In addition, these BioInks are animal-free, exhibit optimal rheological properties at room temperature, support

high cell viability across multiple cell types, and are biocompatible and non-immunogenic.

"These patent allowances and grants represent

important milestones in executing our strategy to expand the clinical and commercial applications of our rhCollagen platform into high-value

aesthetic and regenerative medicine markets," said Yehiel Tal, Chief Executive Officer of CollPlant. "The United States and

South Korea are strategically important markets in aesthetic medicine, and strengthening our intellectual property position in these regions

further enhances the long-term value of our technology."

Cost Reductions and Program Prioritization

In November 2025, CollPlant updated its expense

forecast and implemented a cost-reduction and workforce optimization plan. As part of this initiative, the Company adjusted its resource

allocation and reduced its workforce by approximately 25%.

Redesigned Corporate Website